Nanobiotix: Trading Halt on Euronext Paris for a Global Securities Offering
Nanobiotix announces a temporary suspension of trading of its ordinary shares on Euronext Paris starting from the market opening at 9:00 AM (CEST) on Thursday, in connection with a global securities offering.
Trading Suspension and Context of the Offering
The biotechnology company temporarily suspends the trading of its ordinary shares on the regulated Euronext market in Paris. This suspension is part of a global offering consisting of two components: a public offering of American Depositary Shares (ADS) in the United States, and an offering of ordinary shares along with pre-financed warrant subscriptions reserved for qualified investors in Europe and certain other countries (excluding the United States and Canada).
The suspension will allow for the confirmation of allocations to investors and the announcement of the final terms of the global offering. Trading on Euronext Paris is expected to resume on May 21, 2026, around 3:30 PM (Paris time) / 9:30 AM (New York time).
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company in advanced phase, founded in 2003, headquartered in Paris. It has been listed on Euronext in Paris since 2012 and on the Nasdaq Global Select Market since December 2020. The company has subsidiaries, notably in Cambridge, Massachusetts, and owns over 25 patent families associated with three nanotechnology platforms covering oncology, bioavailability and biodistribution, as well as central nervous system disorders.
